| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Delphinidin 3-O-rutinoside chloride targets multiple cellular pathways involved in oxidative stress, inflammation, and cell survival. As an anthocyanin, it acts as a potent antioxidant by scavenging free radicals and chelating metal ions. The compound also exhibits anti-inflammatory effects by modulating inflammatory cytokine production and signaling pathways. Its effects on cell survival are mediated through the modulation of various signaling pathways.
|
|---|---|
| ln Vitro |
In cell-free biochemical systems, Delphinidin 3-O-rutinoside chloride exhibits potent antioxidant activity as measured by DPPH, ABTS, and FRAP assays. The compound's ability to scavenge free radicals and reduce oxidative stress can be assessed in cell-free systems. Its anti-inflammatory activity can be evaluated by measuring its effects on purified inflammatory mediators or signaling components.
|
| ln Vivo |
In cell-based assays, Delphinidin 3-O-rutinoside chloride exhibits antioxidant effects by reducing intracellular reactive oxygen species (ROS) levels and protecting cells from oxidative stress-induced damage. The compound's anti-inflammatory effects are evaluated by measuring the inhibition of pro-inflammatory cytokine production in immune cells. Its effects on cell proliferation and survival are assessed in various cell lines.
|
| Enzyme Assay |
The cell-free assay for antioxidant activity involves measuring the compound's ability to scavenge free radicals such as DPPH, ABTS, or to reduce ferric ions (FRAP). The compound is incubated with the radical solution, and the decrease in absorbance is measured spectrophotometrically. The IC50 or EC50 is determined from dose-response curves. Metal chelation activity can be assessed using ferrozine-based assays.
|
| Cell Assay |
Cell-based assays for Delphinidin 3-O-rutinoside chloride involve culturing relevant cell lines and treating them with the compound at concentrations ranging from 0.1 to 1000 μM. Antioxidant activity is assessed by measuring the compound's ability to protect cells from oxidative stress induced by H2O2 or other oxidants. Anti-inflammatory effects are assessed by measuring cytokine production in LPS-stimulated immune cells. Cell viability is assessed using MTT or CCK-8 assays.
|
| Animal Protocol |
There is no established animal experimental protocol for Delphinidin 3-O-rutinoside chloride specifically. As a natural anthocyanin with antioxidant and anti-inflammatory activities, the compound could potentially be evaluated in animal models of oxidative stress, inflammation, and metabolic diseases. Typical studies involve administration of the compound to mice via oral or intraperitoneal routes.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Delphinidin 3-O-rutinoside chloride have not been extensively reported. As an anthocyanin glycoside with a molecular weight of approximately 627.5 g/mol, the compound would be expected to have limited oral bioavailability due to poor absorption and extensive metabolism. The compound is typically metabolized by gut microbiota and undergoes phase II conjugation. Further pharmacokinetic studies would be required.
|
| Toxicity/Toxicokinetics |
Delphinidin 3-O-rutinoside chloride is intended for research use only and lacks established toxicity profiles for therapeutic applications. Standard laboratory safety precautions should be observed when handling this natural product. As a compound with diverse biological activities, it may have effects on multiple cellular processes. The compound is generally considered to have low toxicity based on its natural occurrence in foods.
|
| References | |
| Additional Infomation |
Delphinidin 3-O-rutinoside chloride is a research-grade natural product supplied for antioxidant and anti-inflammatory research. It is not an approved pharmaceutical and has no clinical trial history. The compound is a natural anthocyanin pigment found in various fruits and vegetables. This product is intended for research use only.
|
| Molecular Formula |
C27H31CLO16
|
|---|---|
| Molecular Weight |
646.98
|
| Exact Mass |
365.909
|
| CAS # |
15674-58-5
|
| PubChem CID |
192918
|
| Appearance |
Brown to reddish brown solid powder
|
| Hydrogen Bond Donor Count |
11
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
44
|
| Complexity |
902
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=CC4=C(C=C(C=C4[O+]=C3C5=CC(=C(C(=C5)O)O)O)O)O)O)O)O)O)O)O.[Cl-]
|
| InChi Key |
ZOQQFMKYEOHRMC-KFOCXKDFSA-N
|
| InChi Code |
InChI=1S/C27H30O16.ClH/c1-8-18(32)21(35)23(37)26(40-8)39-7-17-20(34)22(36)24(38)27(43-17)42-16-6-11-12(29)4-10(28)5-15(11)41-25(16)9-2-13(30)19(33)14(31)3-9;/h2-6,8,17-18,20-24,26-27,32,34-38H,7H2,1H3,(H4-,28,29,30,31,33);1H/t8-,17+,18-,20+,21+,22-,23+,24+,26+,27+;/m0./s1
|
| Chemical Name |
(2R,3R,4R,5R,6S)-2-[[(2R,3S,4S,5R,6S)-6-[5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chromenylium-3-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methoxy]-6-methyloxane-3,4,5-triol;chloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5456 mL | 7.7282 mL | 15.4564 mL | |
| 5 mM | 0.3091 mL | 1.5456 mL | 3.0913 mL | |
| 10 mM | 0.1546 mL | 0.7728 mL | 1.5456 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
